Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The largest-ever genetic study on Alzheimer's disease has identified 127 genomic risk regions — 48 of them brand new — and found that common genetic variants explain about 16% of disease risk, nearly triple previous estimates. The international study, drawing on data from ~2.8 million people, also spotlights brain immune cells (microglia) and specific neuron types as key players in disease development, opening new doors for treatment research.
The largest genetic study on Alzheimer's disease to date has reshaped our understanding of how much our DNA influences the risk of developing the condition. Published in Nature, the international study analyzed genetic data from nearly 2.8 million people and identified 127 genomic regions linked to Alzheimer's risk — including 48 that had never been flagged before. The findings suggest that common genetic variants collectively explain about 16% of Alzheimer's disease liability in European-ancestry populations, nearly three times the ~5% estimated by earlier methods.
Beyond the numbers, the study points to brain immune cells called microglia as central players in Alzheimer's biology, with newly identified genetic signals tied to immune activation, cellular cleanup, and amyloid processing. For the first time, researchers also linked specific neuron types to genetic risk, broadening the picture beyond immunity alone. Five potential drug targets — including SYK and AXL, both involved in immune responses to amyloid — were flagged for further investigation.
By the Numbers
Why it matters: These findings give researchers a far more detailed genetic map of Alzheimer's disease, identifying new biological pathways and potential drug targets. While polygenic risk scores aren't ready for routine clinical use yet — especially in non-European populations — this study lays critical groundwork for more precise risk prediction and the development of next-generation therapies.
